Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease

The identification of cell‐free circulating mitochondrial DNA (ccf‐mtDNA) in early‐stage Alzheimer's disease (AD) raised the possibility that the same neurodegenerative effect could be observed in Parkinson's disease (PD). Here, and for the first time, we investigated the role of ccf‐mtDNA...

Full description

Saved in:
Bibliographic Details
Published in:Annals of neurology 2015-12, Vol.78 (6), p.1000-1004
Main Authors: Pyle, Angela, Brennan, Rebecca, Kurzawa-Akanbi, Marzena, Yarnall, Alison, Thouin, Anais, Mollenhauer, Brit, Burn, David, Chinnery, Patrick F., Hudson, Gavin
Format: Article
Language:English
Subjects:
Aged
Alzheimer's disease
Biomarkers
Biomarkers - cerebrospinal fluid
Deoxyribonucleic acid
DNA
DNA, Mitochondrial - cerebrospinal fluid
Female
Humans
Male
Middle Aged
Mitochondrial DNA
Parkinson Disease - cerebrospinal fluid
Parkinson's disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The identification of cell‐free circulating mitochondrial DNA (ccf‐mtDNA) in early‐stage Alzheimer's disease (AD) raised the possibility that the same neurodegenerative effect could be observed in Parkinson's disease (PD). Here, and for the first time, we investigated the role of ccf‐mtDNA in PD, identifying a significant reduction of ccf‐mtDNA in PD patient cerebrospinal fluid (CSF) when compared to controls. Our data demonstrates that CSF ccf‐mtDNA is not only a powerful biomarker for PD, but, given that the effect is also observed in AD, is likely a biomarker for neurodegeneration. Ann Neurol 2015;78:1000–1004
ISSN:0364-5134
1531-8249
DOI:10.1002/ana.24515